Table 2.
Pathological response by germline BRCA mutation status and Stage
| All Patients | KU | Spanish | P* | |
|---|---|---|---|---|
| All patients | N=183 | N=68 | N=115 | |
| pCR | N (%) (95% CI) | N (%) (95% CI) | N (%) (95% CI) | |
| Yes | 100 (55%) (48%, 62%) | 44 (65%) (54%, 76%) | 56 (49%) (40%, 58%) | 0.046 |
| No | 83 (45%) (38%, 52%) | 24 (35%) (24%, 46%) | 59 (51%) (42%, 60%) | |
| RCB 0 +1 | ||||
| Yes | 125 (68%) (61%, 75%) | 55 (81%) (72%, 90%) | 70 (61%) (52%, 70%) | 0.005 |
| No | 58 (32%) (25%, 39%) | 13 (19%) (10%, 28%) | 45 (39%) (30%, 48%) | |
| BRCA wild type | N=133 | N=48 | N=85 | |
| pCR | N (%) (95% CI) | N (%) (95% CI) | N (%) (95% CI) | |
| Yes | 75 (56%) (48%, 64%) | 31 (65%) (52%, 78%) | 44 (52%) (41%, 63%) | 0.20 |
| No | 58 (44%) (36%, 52%) | 17 (35%) (22%, 48%) | 41 (48%) (37%, 59%) | |
| RCB 0 +1 | ||||
| Yes | 92 (69%) (61%, 77%) | 39 (81%) (70%, 92%) | 53 (62%) (52%, 72%) | 0.031 |
| No | 41 (31%) (23%, 39%) | 9 (19%) (8%, 30%) | 32 (38%) (28%, 48%) | |
| BRCA mutation positive | N=27 | N=15 | N=12 | |
| pCR | N (%) (95% CI) | N (%) (95% CI) | N (%) (95% CI) | |
| Yes | 16 (59%) (40%, 78%) | 11 (73%) (51%, 95%) | 5 (42%) (14%, 70%) | 0.13 |
| No | 11 (41%) (22%, 60%) | 4 (27%) (5%, 49%) | 7 (58%) (30%, 86%) | |
| RCB 0+1 | ||||
| Yes | 19 (70%) (53%, 87%) | 12 (80%) (60%, 100%) | 7 (58%) (30%, 86%) | 0.40 |
| No | 8 (30%) (13%, 47%) | 3 (20%) (0%, 40%) | 5 (42%) (14%, 70%) | |
| BRCA status unknown | N=23 | N=5 | N=18 | |
| pCR | N (%) (95% CI) | N (%) (95% CI) | N (%) ( 95% CI) | 1 |
| Yes | 9 (39%) (19%, 59%) | 2 (40%) (3%, 83%) | 7 (39%) (16%, 62%) | |
| No | 14 (61%) (41%, 81%) | 3 (60%) (17%, 103%) | 11 (61%) (38%, 84%) | |
| RCB 0 +1 | ||||
| Yes | 14 (61%) (41%, 81%) | 4 (80%) (45%, 115%) | 10 (56%) (33%, 79%) | 0.61 |
| No | 9 (39%) (19%, 56%) | 1 (20%) (15%, 55%) | 8 (44%) (21%, 67%) | |
| TNM stage I and II | N=124 | N=58 | N=66 | |
| pCR | N (%) (95% CI) | N (%) (95% CI) | N (%) ( 95% CI) | |
| Yes | 78 (63%) (54%, 71%) | 40 (69%) (57%, 81%) | 38 (58%) (46, 70%) | 0.20 |
| No | 48 (37%) (29%, 46%) | 18 (31%) (19%, 43%) | 28(42%) (30%, 54%) | |
| RCB 0 +1 | ||||
| Yes | 95 (77%) (70%, 84%) | 50 (86%) (77%, 95%) | 45 (68%) (57%, 79%) | 0.02 |
| No | 29 (23%) (16%, 30%) | 8 (14%) (5%, 23%) | 21 (32%) (21%, 43%) | |
| TNM stage III | N=59 | N=10 | N=49 | |
| pCR | N (%) (95% CI) | N (%) (95% CI) | N (%) (95% CI) | |
| Yes | 22 (37%) (25%, 49%) | 4 (40%) (10%, 70%) | 18 (37%) (23%, 51%) | 1.0 |
| No | 37 (63%) (51%, 75%) | 6 (60%) (30%, 90%) | 31(63%) (49%, 77%) | |
| RCB 0 + 1 | ||||
| Yes | 29 (49%) (36%, 62%) | 5 (50%) (19%, 81%) | 24 (49%) (35%, 63%) | 1.0 |
| No | 30 (51% (38%, 64%) | 5 (50%) (19%, 81%) | 25 (51%) (37%, 65%) | |
*
Fisher Exact test.